Thea Pharma markets a suite of leading eye-care drugs that have been approved by the U.S. Food and Drug Administration (FDA), including CYKLX, ZOLYMBUS, IYUZEH, Zioptan®, Cosopt®, Cosopt® PF, Azasite®, Akten®, and Betimol®, as well as AcellFX Acellular Amniotic Membrane and the portfolio of iVIZIA dry-eye drops and eyelid hygiene products. Strategic Payer Account Management: Develop and execute account-specific strategies for an assigned national portfolio of priority payer accounts, including national and regional commercial health plans, MACs, PBMs and other strategically important payer organizations, in alignment with portfolio and brand access objectives.